Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2022—Roche launched its Digital LightCycler system, the company’s first digital polymerase chain reaction system, for precise DNA and RNA analysis in areas such as oncology and infectious diseases. The instrument features three unique reaction plates, six channel multiplexing capabilities, and a 5× concentrated master mix reagent. Run time is two to four hours with up to 96 samples per run.
October 2022—Thermo Fisher Scientific launched the CE-IVD Oncomine Dx Express test and Oncomine Reporter Dx for use in clinical labs.
October 2022—DiaSorin received 510(k) clearance from the FDA for its Simplexa COVID-19 Direct kit. The sample-to-answer test detects SARS-CoV-2 directly from nasopharyngeal or nasal swab specimens and is designed for use on the Liaison MDX system. The test targets two regions of the viral genome and results are available in a little over an hour.
October 2022—StatLab has released TissueGuard, an agarose gel that stabilizes and protects small or fragile specimens during processing while allowing reagent penetration. TissueGuard can be used for cytology samples, including fine-needle aspirates, urine and nongynecological specimens, and other specimens using cell block preparation, and for histology applications, including needle biopsies, nerves, small arteries, aggregates, lymph nodes, and small tissue fragments. The gel does not stain and remains invisible when blocks are cut.
October 2022—Audit MicroControls has announced the availability of its Linearity LQ hs-CRP for Ortho Vitros. The product is intended to simulate human patient serum samples for determining linearity, calibration verification, and verification of the reportable range for hs-CRP. The product consists of five levels of human serum and has an open-vial stability of five days when stored at 2° to 8°C.
October 2022—Grenova released a case study in which enzyme-linked immunosorbent assay validation was performed with pipette tips that were washed and reused five times using the company’s Tipnovus system. Grenova says its technology decreased overall cost per clinical diagnostic test, resulting in an increased profitability margin, and that the laboratory also decreased plastic waste.
October 2022—Oxford Immunotec, a division of PerkinElmer, announced FDA approval of its T-Cell Select reagent kit for automating the company’s T-Spot.TB test workflow for in vitro diagnostic use by certified laboratories.
October 2022—Verichem Laboratories offers liquid-stable, ready-to-use clinical reference materials for protein testing. The multilevel and combined Total Protein/Albumin Standard Kit, along with the optional and standalone level F, and the Microprotein Standard Kit are designed and manufactured for the calibration and calibration verification of albumin and total protein assays on a range of clinical testing systems, including from Abbott Diagnostics, Beckman Coulter, Roche Diagnostics, and Siemens Healthineers.
October 2022—Bio-Rad extended its range of StarBright dyes with the StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes, to provide greater flexibility in multicolor flow cytometry panels. The company says the dyes offer improved brightness with narrow excitation and emission profiles for precise resolution, are resistant to photobleaching, and do not lose signal in fixation. They are compatible with the Bio-Rad ZE5 cell analyzer and S3e cell sorter and most flow cytometers without the need for special buffers.
October 2022—Siemens Healthineers released its CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay and Clinitest Rapid COVID-19 plus Influenza Antigen Test.
